[go: up one dir, main page]

BRPI0922367A2 - enzastaurin para o tratamento de câncer - Google Patents

enzastaurin para o tratamento de câncer

Info

Publication number
BRPI0922367A2
BRPI0922367A2 BRPI0922367A BRPI0922367A BRPI0922367A2 BR PI0922367 A2 BRPI0922367 A2 BR PI0922367A2 BR PI0922367 A BRPI0922367 A BR PI0922367A BR PI0922367 A BRPI0922367 A BR PI0922367A BR PI0922367 A2 BRPI0922367 A2 BR PI0922367A2
Authority
BR
Brazil
Prior art keywords
enzastaurin
cancer treatment
cancer
treatment
Prior art date
Application number
BRPI0922367A
Other languages
English (en)
Inventor
Gopinath Ganji
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0922367A2 publication Critical patent/BRPI0922367A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15Depsipeptides; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0922367A 2008-12-15 2009-12-07 enzastaurin para o tratamento de câncer BRPI0922367A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12245108P 2008-12-15 2008-12-15
PCT/US2009/066925 WO2010074936A2 (en) 2008-12-15 2009-12-07 Enzastaurin for the treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI0922367A2 true BRPI0922367A2 (pt) 2016-05-24

Family

ID=41785627

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922367A BRPI0922367A2 (pt) 2008-12-15 2009-12-07 enzastaurin para o tratamento de câncer

Country Status (11)

Country Link
US (1) US20110288032A1 (pt)
EP (1) EP2376081A2 (pt)
JP (1) JP2012512157A (pt)
KR (1) KR20110084533A (pt)
CN (1) CN102245184A (pt)
AU (1) AU2009330492A1 (pt)
BR (1) BRPI0922367A2 (pt)
CA (1) CA2746085A1 (pt)
EA (1) EA201170821A1 (pt)
MX (1) MX2011006433A (pt)
WO (1) WO2010074936A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3240281A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
CN104271583B (zh) * 2012-01-24 2017-10-24 米伦纽姆医药公司 治疗鼻咽癌的方法
EP2810066B1 (en) * 2012-01-24 2019-07-31 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
SG11201404888SA (en) * 2012-02-17 2014-09-26 Pharmacyclics Inc Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
US20160166632A1 (en) * 2013-07-19 2016-06-16 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
WO2017011314A1 (en) * 2015-07-10 2017-01-19 Paharmacyclics Llc Btk and hdac combinations
WO2020223657A1 (en) * 2019-05-02 2020-11-05 Predictive Technology Group, Inc. Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2236702T3 (es) 1993-12-23 2005-07-16 Eli Lilly And Company Inhibidores de la proteina quinasa c.
WO2006019851A1 (en) * 2004-07-23 2006-02-23 Eli Lilly And Company Methods for diagnosing and treating diabetic microvascular complications
US20090202659A1 (en) * 2005-06-10 2009-08-13 Gimble Jeffrey M Modulation of Peripheral Clocks in Adipose Tissue

Also Published As

Publication number Publication date
CN102245184A (zh) 2011-11-16
EP2376081A2 (en) 2011-10-19
EA201170821A1 (ru) 2011-12-30
MX2011006433A (es) 2011-07-19
US20110288032A1 (en) 2011-11-24
CA2746085A1 (en) 2010-07-01
WO2010074936A3 (en) 2010-09-16
KR20110084533A (ko) 2011-07-25
AU2009330492A1 (en) 2010-07-01
JP2012512157A (ja) 2012-05-31
WO2010074936A2 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
BR112012005594A2 (pt) tratamento de câncer
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
BRPI0810206A2 (pt) Método de tratar câncer
BRPI0922884A2 (pt) compostos para tratamento de câncer
DK2121139T3 (da) Formulations for cancer treatment
BRPI0821660A2 (pt) Combinações de agentes terapêuticos para tratamento de câncer
BRPI1015215A2 (pt) porções de ligação alvo armadas com amatoxina para o tratamento de câncer
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
PT2340042E (pt) Métodos e composições para o tratamento de cancro
BRPI1010874A2 (pt) composição para o tratamento de câncer de próstata
BR112012000502A2 (pt) terapia de combinação para o tratamento de diabetes
BRPI0813670A2 (pt) Compostos para tratamento
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI1006438A2 (pt) terapia adjuvante de cancer
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI1009919A2 (pt) combinações de pentamidina para tratamento de câncer.
BR112012002797A2 (pt) tratamento de câncer de próstata
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI0812040A2 (pt) Indicações para terapia de anti-il-i-beta
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
PT2632452T (pt) Compostos e composições para o tratamento do cancro
BRPI0922367A2 (pt) enzastaurin para o tratamento de câncer
ZA201203449B (en) Sulfoxide derivatives for treating tumors
GB0804496D0 (en) Treating cancer
HUE038563T2 (hu) Rák kezelési eljárás

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.